CURACLE

2:15 PM - 2:30 PM (PDT), Tuesday, June 14, 2022
Curacle is a Korean biopharmaceutical company focused on the discovery, development, and commercialization of innovative global therapeutics for the treatment of aged-related vascular and intractable diseases and cancers. Curacle's research efforts are focused on the development of therapeutics inhibiting endothelial dysfunction by tackling multiple mediators including VEGF, Ang-2, bradykinin, and so on, and maintaining vascular homeostasis which is one of the most essential elements in controlling diseases and aging. We have 11 pipelines ranging from discovery to phase 3 and currently, 9 of them are in clinical stages. Curacle was founded in 2016 and within 5 years Curacle was listed on the Korean Stock market in July of last year. In this process, we received a double AA grade in technology evaluation from the government. And last October, we completed a global licensing deal with a total deal value of 2 billion USD with Thea, a leading independent ophthalmology company in Europe.
Ticker:
curacle
Exchange:
Krw
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
Ophthalmology, Diabetic Nephropathy, Oncology, Acute Coronary Syndrome, UC etc
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5